Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.

The global Focal Segmental Glomerulosclerosis (FSGS) market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Focal Segmental Glomerulosclerosis (FSGS) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Focal Segmental Glomerulosclerosis (FSGS) market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Focal Segmental Glomerulosclerosis (FSGS) in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Focal Segmental Glomerulosclerosis (FSGS) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Variant Pharmaceuticals
ChemoCentryx
Retrophin
Novartis
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Teva Pharmaceutical

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Primary Focal Segmental Glomerulosclerosis
Secondary Focal Segmental Glomerulosclerosis

Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics